College of Food Science and Engineering, Jilin University, 5333 Xi\'an Rd., Changchun, China.
Changchun Polytechnic, 3278 Weixing Road, Changchun, China.
Endocr Metab Immune Disord Drug Targets. 2022;22(5):525-531. doi: 10.2174/1871530321666210917163719.
Probiotics are a group of bacteria that play a critical role in intestinal microbiota homeostasis and may help adjunctively treat certain diseases like metabolic and immune disorders.
We recently generated a space-flight mutated Lactobacillus plantarum SS18-50 with good in vitro probiotic characteristics. In the current research, we designed two in vivo experiments to evaluate whether L. plantarum SS18-50 had the ability to increase beneficial gut bacteria, regulate oxidative status and ameliorate inflammation in mice.
Experiments I: the ICR mice were gavaged with L. plantarum SS18-50 or its wild type L. plantarum GS18 at 10 or 10 CFU/kg BW daily for one month, during which the body weight was recorded weekly. The feces were collected to determine the abundance of two main beneficial bacterial groups including Lactobacillus and Bifidobacterium by selective culturing, while the total triglycerides and cholesterols in sera were determined using commercial kits. Experiment II: the mice were gavaged with loperamide hydrochloride (Lop) to develop oxidative stress and inflammation phenotypes. At the same time, the experimental mice were gavaged with L. plantarum SS18-50 or wild type L. plantarum GS18 at 10 or 10 CFU/kg BW daily for one month. At the end of the experiment, oxidative indicators (SOD and MDA) and inflammatory cytokines (IL-17A and IL-10) were measured by commercial kits.
Results showed that L. plantarum SS18-50 increased the abundance of Lactobacillus and Bifidobacterium in mice after one month's administration. L. plantarum SS18-50 also showed the anti-oxidant activity by increasing SOD and decreasing MDA and exerted the anti-inflammatory effect by increasing IL-10 and decreasing IL-17A in Lop treated mice. Both the wild type stain and the space mutant had such biomedical effects, but L. plantarum SS18-50 was better in increasing gut beneficial bacteria and oxidative regulation than the wild type (P<0.05).
We conclude that L. plantarum SS18-50 has a great potential to serve as a dietary functional probiotic supplement and/or adjunctive treatment strategy.
益生菌是一组在肠道微生物群稳态中起关键作用的细菌,可能有助于辅助治疗代谢和免疫紊乱等某些疾病。
我们最近生成了一株具有良好体外益生菌特性的空间诱变植物乳杆菌 SS18-50。在当前的研究中,我们设计了两项体内实验来评估植物乳杆菌 SS18-50 是否有能力增加有益肠道细菌、调节氧化状态和改善小鼠炎症。
实验 I:ICR 小鼠每日灌胃 10 或 10 CFU/kg BW 的植物乳杆菌 SS18-50 或其野生型植物乳杆菌 GS18,持续一个月,每周记录体重。收集粪便,通过选择性培养来确定两种主要有益细菌群(包括乳酸菌和双歧杆菌)的丰度,同时使用商业试剂盒测定血清中的总甘油三酯和胆固醇。实验 II:用盐酸洛哌丁胺(Lop)灌胃建立氧化应激和炎症表型的小鼠,同时每日灌胃 10 或 10 CFU/kg BW 的植物乳杆菌 SS18-50 或野生型植物乳杆菌 GS18,持续一个月。实验结束时,使用商业试剂盒测定氧化指标(SOD 和 MDA)和炎症细胞因子(IL-17A 和 IL-10)。
结果表明,植物乳杆菌 SS18-50 经一个月给药后增加了小鼠肠道中乳酸菌和双歧杆菌的丰度。植物乳杆菌 SS18-50 还通过增加 SOD 并降低 MDA 显示出抗氧化活性,通过增加 IL-10 并降低 Lop 处理小鼠中的 IL-17A 发挥抗炎作用。野生型菌株和空间突变株均具有这种生物医学作用,但植物乳杆菌 SS18-50 在增加肠道有益细菌和氧化调节方面优于野生型(P<0.05)。
我们得出结论,植物乳杆菌 SS18-50 具有作为膳食功能性益生菌补充剂和/或辅助治疗策略的巨大潜力。